[Malignant pheochromocytoma].
Tanabe
Akiyo
A
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University.
Tsuiki
Mika
M
Takano
Kazue
K
Naruse
Mitsuhide
M
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use; D000310:Adrenal Gland Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D000315:Adrenalectomy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D002395:Catecholamines / Q000032:analysis; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D003937:Diagnosis, Differential; D003952:Diagnostic Imaging; D018095:Germ-Line Mutation; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D010673:Pheochromocytoma / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D013385:Succinate Dehydrogenase / Q000235:genetics; D014750:Vincristine / Q000008:administration & dosage
D015415:Biomarkers; D002395:Catecholamines; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; D014750:Vincristine; D003606:Dacarbazine; D003520:Cyclophosphamide; D013385:Succinate Dehydrogenase